3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors.
Factor IX
Factor VII
Factor Xa inhibitors
Hemorrhage
Hemostatics
Platelet aggregation inhibitors
Prothrombin complex concentrations
Thromboembolism
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
accepted:
11
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
Multiple agents exist for the reversal of oral Factor Xa inhibitor (FXa) associated bleeding, including Coagulation FXa Recombinant, Inactivated zhzo (andexanet alfa) and 4-factor prothrombin complex concentrate (4F-PCC). While classified as a 3F-PCC product, Profilnine contains up to 35 IU of Factor VII (per 100 IU of Factor IX) in addition to therapeutic levels of Factors II, IX, and X, and has demonstrated a similar impact on prothrombin time and blood product usage in non-warfarin related bleeding. This was a retrospective, multicenter study at four medical centers of adult patients who presented with major bleeding associated with oral FXa inhibitors and received either 4F-PCC (n = 64) or 3F-PCC (n = 61). The primary outcome was hemostatic effectiveness. Secondary outcomes included the incidence of thromboembolism, in-hospital mortality, and length of stay. The most common indication for reversal was intracranial bleeding. For the primary outcome, 84% of all patients were rated as effective with no difference noted between the groups (p = 0.81). No significant difference between groups was found in the multivariable analysis adjusting for baseline differences between groups including race, total body weight, type of bleeding, and the use of antiplatelet therapy. There was no difference in the length of stay, in-hospital mortality, or the incidence of thromboembolism between the groups. Overall, no significant differences were found in the effectiveness or safety of 4F-PCC and 3F-PCC use in the management of oral FXa inhibitor-associated bleeding. Further investigations are warranted to explore the use of 3F-PCC for this indication and its safety and effectiveness.
Identifiants
pubmed: 39467897
doi: 10.1007/s11239-024-03052-4
pii: 10.1007/s11239-024-03052-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Kattoor AJ, Pothineni NV, Goel A, Syed M, Syed S, Paydak H et al (2019) Prescription patterns and outcomes of patients with atrial fibrillation treated with direct oral anticoagulants and warfarin: a real-world analysis. J Cardiovasc Pharmacol Ther 24(5):428–434. https://doi.org/10.1177/1074248419841634
doi: 10.1177/1074248419841634
pubmed: 31035795
Christensen H, Cordonnier C, Korv J, Lal A, Ovesen C, Purrucker JC et al (2019) European stroke organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Eur Stroke J 4(4):294–306. https://doi.org/10.1177/2396987319849763
doi: 10.1177/2396987319849763
pubmed: 31903428
pmcid: 6921939
Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW et al (2020) 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol 76(5):594–622. https://doi.org/10.1016/j.jacc.2020.04.053
doi: 10.1016/j.jacc.2020.04.053
pubmed: 32680646
Baugh CW, Levine M, Cornutt D, Wilson JW, Kwun R, Mahan CE et al (2020) Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. Ann Emerg Med 76(4):470–485. https://doi.org/10.1016/j.annemergmed.2019.09.001
doi: 10.1016/j.annemergmed.2019.09.001
pubmed: 31732375
Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM et al (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care 24(1):6–46. https://doi.org/10.1007/s12028-015-0222-x
doi: 10.1007/s12028-015-0222-x
pubmed: 26714677
Panos, N. G., Cook, A. M., John, S., Jones, G. M., & Neurocritical Care Society Pharmacy Study, G (2020) Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates. Circulation 141(21):1681–1689. https://doi.org/10.1161/CIRCULATIONAHA.120.045769
doi: 10.1161/CIRCULATIONAHA.120.045769
Ammar AA, Ammar MA, Owusu KA, Brown SC, Kaddouh F, Elsamadicy AA et al (2021) Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage. Neurocrit Care 35(1):255–261. https://doi.org/10.1007/s12028-020-01161-5
doi: 10.1007/s12028-020-01161-5
pubmed: 33403588
pmcid: 10273779
CSL Behring. Kcentra (Prothrombin Complex Concentrate (Human)) [package insert]. U.S. Food and Drug Administration. website. https://www.fda.gov/media/85512/download?attachment . Accessed May 10, 2024.
Grifols Biologicals Inc. Profilnine SD (Factor IX Complex) [package insert]. U.S. Food and Drug Administration. website. https://www.fda.gov/media/80956/download . Accessed May 10, 2024.
DeAngelo J, Jarrell DH, Cosgrove R, Camamo J, Edwards CJ, Patanwala AE (2018) Comparison of blood product use and costs with use of 3-factor versus 4-factor prothrombin complex concentrate for off-label indications. Am J Health Syst Pharm 75(15):1103–1109. https://doi.org/10.2146/ajhp180076
doi: 10.2146/ajhp180076
pubmed: 29941507
Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ et al (2014) Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 12(9):1428–1436. https://doi.org/10.1111/jth.12599
doi: 10.1111/jth.12599
pubmed: 24811969
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579. https://doi.org/10.1161/CIRCULATIONAHA.111.029017
doi: 10.1161/CIRCULATIONAHA.111.029017
pubmed: 21900088
Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL et al (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128(11):1234–1243. https://doi.org/10.1161/CIRCULATIONAHA.113.002283
doi: 10.1161/CIRCULATIONAHA.113.002283
pubmed: 23935011
pmcid: 6701181
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. https://doi.org/10.1016/j.jbi.2008.08.010
doi: 10.1016/j.jbi.2008.08.010
pubmed: 18929686
Voils SA, Baird B (2012) Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res 130(6):833–840. https://doi.org/10.1016/j.thromres.2012.10.001
doi: 10.1016/j.thromres.2012.10.001
pubmed: 23137921
Costa OS, Baker WL, Roman-Morillo Y, McNeil-Posey K, Lovelace B, White CM et al (2020) Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review. BMJ Open 10(11):e040499. https://doi.org/10.1136/bmjopen-2020-040499
doi: 10.1136/bmjopen-2020-040499
pubmed: 33154059
pmcid: 7646359